Terminalia catappa attenuates urokinase-type plasminogen activator expression through Erk pathways in Hepatocellular carcinoma

Yeh, Chao‐Bin; Yu, Yung Luen; Lin, Chiao‐Wen; Chiou, Hui‐Ling; Hsieh, Ming Ju; Yang, Shun Fa

doi:10.1186/1472-6882-14-141

Cited by 16 publications

(14 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Huh7 cells treated with TCE led to a reduction in the activities, protein levels, and mRNA levels of u‐PA. TCE inhibited the effects of u‐PA by reducing the phosphorylation of ERK1/2 pathway . The present study revealed that TCE elicited antimetastatic effects on cervical cancer cells by inhibiting the activity of the MMP‐9 and ERK 1/2 pathways.…”

Section: Discussionsupporting

confidence: 56%

Antimetastatic effects of Terminalia catappa leaf extracts on cervical cancer through the inhibition of matrix metalloprotein‐9 and MAPK pathway

Lee

Yang

Wang

et al. 2018

Environmental Toxicology

View full text Add to dashboard Cite

The effects of Terminalia catappa leaf extracts (TCE) have been widely investigated, including its antioxidative, anti-inflammatory, and antidiabetic activity, as well as its antimetastatic effects on several types of human cancer. However, no study has examined the antimetastatic potential of TCE in cervical cancer cells. This study aimed to elucidate the potential antimetastatic properties of ethanol extracts of Terminalia catappa in 12-O-tetradecanoylphorbol-13-acetate treated human cervical cancer cells and investigate the signaling pathway of this process. We demonstrated that TCE elicited very low cytotoxicity and significantly inhibited cellular migration and invasion in human HeLa and SiHa cervical cancer cells. Moreover, the gelatin zymography, reverse transcription-polymerase chain reaction (RT-PCR), and real-time PCR analysis revealed that the activity and mRNA level of matrix metalloproteinase-9 (MMP-9) were inhibited by TCE in a concentration-dependent manner.The Western blot results demonstrated that the highest concentration of TCE (100 μg/ml) reduced the phosphorylation of extracellular signal-regulated kinases 1/2 (ERK1/2) by 46% in the HeLa cell lines. In conclusion, it was revealed that TCE exerted antimetastatic effects on cervical cancer cells by inhibiting the expression of MMP-9 through the ERK1/2 pathway. K E Y W O R D S cervical cancer, MAPK pathway, migration, MMP-9, Terminalia catappa 1 | INTRODUCTION Cervical cancer is one of the leading causes of cancer death and the 4th most frequently occurring malignancy among women worldwide and more than 260 000 women die of cervical cancer annually. 1 Moreover, International Agency for Research on Cancer (IARC) assessed the incidence rate of cervical cancer as 19.0 women per 100 000. 2 Most patients with cervical cancer present with abnormal vaginal bleeding or a cervical mass. 3 Lesion size and pelvic node metastases are vital prognostic factors in cervical cancer. 4 The Chung-Yuan Lee and Shun-Fa Yang contributed equally to the work.

show abstract

Section: Discussionsupporting

confidence: 56%

Antimetastatic effects of Terminalia catappa leaf extracts on cervical cancer through the inhibition of matrix metalloprotein‐9 and MAPK pathway

Lee

Yang

Wang

et al. 2018

Environmental Toxicology

View full text Add to dashboard Cite

show abstract

“…Terminalia catappa Linn. plant has been investigated in various pharmaceutical studies as it contains a variety of chemical components (Pandya et al, 2013; Yeh et al, 2014). T. catappa L. leaf extracts exhibit biological activities, including antioxidant (punicalagin, punicalin, terfluvina A and B, chebulic acid, benzoic acid, cumaric, and its derivatives) (Chen and Li, 2006; Chyau et al, 2006; Kinoshita et al, 2007), antidiabetic (β-carotene) (Anand et al, 2015), anticancer (punicalagin) (Naitik et al, 2012), antiviral (ellagic acid) (Tan et al, 1991), anti-inflammatory (triterpenic acids, especially ursolicacid and its derivatives) (Fan et al, 2004), antimicrobial (flavones and flavanols) (Kloucek et al, 2005; Nair and Chanda, 2008; Shinde et al, 2009), and hepato-protective activities (punicalagin, punicalin) (Kinoshita et al, 2007).…”

Section: Introductionmentioning

confidence: 99%

Phytochemical Characterization of Terminalia catappa Linn. Extracts and Their antifungal Activities against Candida spp.

Terças

Monteiro²,

Moffa³

et al. 2017

Front. Microbiol.

View full text Add to dashboard Cite

Terminalia catappa Linn bark is used to treat dysentery by various populations in Southeast Asian countries, and its leaves have also been used in traditional medicine to treat hepatitis in India and the Philippines. Here, the antifungal actions of crude hydro-alcoholic extract (TcHE) and fractions from T. catappa leaves were assessed via the agar diffusion and microdilution tests on Candida reference strains and clinical isolates from patients with acquired immunodeficiency syndrome (AIDS). Additionally, the potential cytotoxic effects of TcHE were assessed on cultured human peripheral blood mononuclear cells (PBMC). T. catappa fractions and sub-fractions were analyzed by gas chromatography coupled to mass spectrometry with electron impact (GC/MS/EI), high-performance liquid chromatography coupled to mass spectrometry “electrospray” ionization in positive mode (HPLC/MS/MS/ESI+) and hydrogen nuclear magnetic resonance (1HNMR). TcHE and its fractions were able to inhibit the growth of all tested Candida strains with the n-butanol (FBuOH) fraction presenting the best antifungal activity. Testing of different FBuOH sub-fractions (SF) showed that SF10 was the most active against Candida spp. Fractioning of SF10 demonstrated that 5 out of its 15 sub-fractions were active against Candida spp., with SF10.5 presenting the highest activity. Chemical analysis of SF10 detected hydrolysable tannins (punicalin, punicalagin), gallic acid and flavonoid C-glycosides. Overall, the results showed that T. catappa L. leaf extract, fractions and sub-fractions were antifungal against Candida spp. and may be useful to treat diseases caused by this fungus.

show abstract

“…(3) Alpha-l-fucosidase (AFU) is a lysosomal enzyme present in all mammalian cells and it has been proposed as a promising tumor marker since many studies reported increased AFU serum levels in patients with cirrhosis and HCC [96] . (4) Urokinase-type plasminogen activator(UROK) expression may be a potent therapeutic target of HCC [97] . (5) Peroxiredoxin 6 (PRDX6) may be a candidate biomarker for early HCC diagnosis [28] .…”

Section: Comparison Of Urinary Proteins In Different Tumor Modelsmentioning

confidence: 99%

Early changes in the urine proteome in a rat liver tumor model

Zhang

Gao

2019

Preprint

View full text Add to dashboard Cite

Urine, as a potential biomarker source among the body fluids, can accumulate many changes in the body due to the lack of a mechanism to maintain a homeostatic state. Previous studies have demonstrated that proteomic technology can find many potential biomarkers to reflect different diseases in the urine.This study aims to detect early changes in the urinary proteome in a rat liver tumor model. The tumor model was established with the Walker-256 carcinosarcoma cell line (W256). Compared to before the injection, ninety-five differential proteins were significantly changed in the experimental rats. At day 3, twelve proteins were identified in the absence of pathological changes, and four of them were altered at all four time-points (B2MG, VCAM1, HA11, and LG3BP). Seven had previously been associated with liver cancer. At day 5, fifty-two differential proteins were identified. At day 7 and day 11, there was a significant decrease in the body weight of the rats, and tumor tissue was observed in the liver. Fifty-two and forty differential proteins were changed significantly at day 7 and day 11, respectively. Of the proteins that were identified at these three time-points, and twenty-four were reported to be associated with liver cancer. Comparing the differential urinary proteins and biological processes of liver tumor model with those in different models of W256 grown in other organs, specific differential protein patterns were found among the four models, which indicates that the differential urinary proteins can reflect the differences when the same tumor cell grown in different organs.Significance: This study demonstrated that (1) the rat liver tumor model caused early changes in urinary proteins may give new insight into the early diagnosis of liver cancer; (2) the same tumor cell grown in different organs can be reflected in differential urinary proteins.All rats were housed under a standard 12-h light/12-h dark cycle, and the room temperature and humidity were maintained at a standard level (22 ± 1 °C, 65-70%). Tumor cell line and CultureWalker 256 tumor cells were cultured in the ascitic fluid of Wistar rats. All cells were harvested from the rats who were given an intraperitoneal injection of 107 Walker 256 carcinoma cells after two cycles of 7 d cell passage. Then, W256 cells were resuspended in phosphate-buffered saline (PBS) before injection. The viability of the cells was detected by the Trypan blue exclusion test using a Neubauer chamber. Rat models of liver cancerA tumor-bearing animal model was established in this study. All Wistar rats were randomly divided into different groups: the control group (n =5), and the Walker-256 (W256) tumor-bearing group (n =12).After anesthesia, the left medial lobe of the liver was exposed. W256 cells (2.5× 10 5 ) were visually injected under the hepatic capsule into this lobe. The injection volume is 0.1 ml. An equal volume of PBS was also injected into the same location of the control rats. Histological analysisIn the W256 model, the livers of the experimental and cont...

show abstract

Terminalia catappa attenuates urokinase-type plasminogen activator expression through Erk pathways in Hepatocellular carcinoma

Cited by 16 publications

References 43 publications

Antimetastatic effects of Terminalia catappa leaf extracts on cervical cancer through the inhibition of matrix metalloprotein‐9 and MAPK pathway

Antimetastatic effects of Terminalia catappa leaf extracts on cervical cancer through the inhibition of matrix metalloprotein‐9 and MAPK pathway

Phytochemical Characterization of Terminalia catappa Linn. Extracts and Their antifungal Activities against Candida spp.

Early changes in the urine proteome in a rat liver tumor model

Contact Info

Product

Resources

About